ArticleTranslational cancer research2026
Personalized prediction of sequential therapeutic responses in HR+/HER2-low breast cancer using patient-derived organoids.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The clinically recommended treatment for hormone receptor-positive/human epidermal growth factor receptor 2-low (HR+/HER2-low) advanced breast cancer involves endocrine therapy (e.g., fulvestrant) followed by antibody-drug conjugates (ADCs) such as trastuzumab deruxtecan (T-DXd; formerly DS-8201) and sacituzumab govitecan (SG). However, the therapeutic outcomes of this sequential regimen remain suboptimal, and direct evidence is lacking as to whether this sequence is optimal. Additionally, the sequence of DS-8201 and SG is also unknown. Patient-derived organoids (PDOs) have emerged as a promising preclinical tool, shown to predict personalized drug responses and correlate well with clinical outcomes. Therefore, using PDOs from HR+/HER2-low breast cancer, this study aims to systematically evaluate the antitumor effects of different administration sequences involving fulvestrant and ADCs (i.e., DS-8201 or SG), as well as DS-8201 and SG and to provide evidence for optimizing treatment sequencing. Methods: PDOs were established from fresh breast cancer tissues and characterized by immunohistochemistry (IHC), hematoxylin and eosin (H&E) staining, and immunofluorescence (IF) to confirm histopathological and phenotypic features fidelity to original tumors. Organoid viability was assessed using the CellTiter-Glo 3D (CTG-3D) assay, and morphological changes were monitored by bright-field microscopy. After treatment with fulvestrant, DS-8201, or SG alone, IHC and IF were performed to detect key proteins involved in the mechanism of action of SG and DS-8201. Results: Our results demonstrated that administering DS-8201 or SG followed by fulvestrant yielded superior antitumor effects compared with the reverse sequence (fulvestrant followed by ADCs). Moreover, organoids revealed marked patient heterogeneity in response to the sequential administration of DS-8201 and SG (i.e., DS-8201 then SG Conclusions: The sequence of DS-8201/SG followed by fulvestrant is a more suitable treatment regimen than the conventional sequence (fulvestrant followed by ADCs) for HR+/HER2-low breast cancer. This study provides important preclinical evidence supporting the optimization of therapy sequences in personalized medicine and advances the application of organoid-based models in oncology research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.